Biomed Valley Discoveries Announces First Patient Dosed in Phase 2 Study of Its First-in-Class ERK 1/2 Inhibitor Ulixertinib in People with Histiocytosis Biomed Valley Discoveries today announced that the first patient has been dosed in a Phase 2 study of ulixertinib for the treatment of histiocytosis.

GenesisCare and Telix Enter into Strategic Collaboration Agreement to Accelerate Patient Access to New Treatments MELBOURNE, Australia and SYDNEY, Australia, Oct. 10, 2018 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on...

Midatech Pharma PLC (“Midatech”, the “Company” or the “Group”) Pre-Close Trading Update OXFORD, United Kingdom, Jan. 06, 2016 (GLOBE NEWSWIRE) -- Midatech Pharma (AIM:MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising...